AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18060091 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 mcg once daily
Number of subjects: 913
Study 18060091 — intervention group
Group type: COMPARATOR
Intervention: Placebo (usual care minus inhaled anticholinergics)
Number of subjects: 913
Study 15585213 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg
Number of subjects: 7
Study 15585213 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 40 mg
Number of subjects: 7
Study 12373467 — intervention group
Group type: EXPERIMENTAL
Intervention: APRV with spontaneous breathing
Number of subjects: 12
Study 12373467 — intervention group
Group type: COMPARATOR
Intervention: APRV without spontaneous breathing (same V(E))
Number of subjects: 12
Study 12373467 — intervention group
Group type: COMPARATOR
Intervention: APRV without spontaneous breathing (same Paw)
Number of subjects: 12
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 40 mg twice daily
Number of subjects: 1160
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily
Number of subjects: 1160
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 120 mg twice daily
Number of subjects: 1160
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg twice daily
Number of subjects: 1160
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 60 mg twice daily for 6 months
Number of subjects: 1160
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 80 mg twice daily for 3 months
Number of subjects: 1160
Study 10335761 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine HCl 240 mg once daily for 12 months
Number of subjects: 1160
Study 10335761 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine HCl (various doses)
Number of subjects: 1160
Study 10335761 — intervention group
Group type: COMPARATOR
Intervention: Fexofenadine HCl
Number of subjects: 1160
Study 7785008 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training (EMT) for 15 minutes twice daily for four weeks using a pressure threshold device; expiratory threshold set at 30% of PEmax.
Number of subjects: 12
Study 7785008 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 12
Study 1483317 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 26
Study 4081404 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalidixic acid (1 g X 3)
Number of subjects: 82
Study 4081404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivmecillinam (200‐400 mg X 3)
Number of subjects: 82
Study 4081404 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 82
Study 31252598 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction by 20% of TDEE (CR I)
Number of subjects: 94
Study 31252598 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction by 30% of TDEE (CR II)
Number of subjects: 94
Study 31252598 — intervention group
Group type: EXPERIMENTAL
Intervention: Both CR I and CR II diets
Number of subjects: 94
Study 31252598 — intervention group
Group type: COMPARATOR
Intervention: Comparison between CR I and CR II
Number of subjects: 94
Study 30320676 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified lateral tarsal strip (M‐LTS)
Number of subjects: 8
Study 30320676 — intervention group
Group type: COMPARATOR
Intervention: Conventional lateral tarsal strip (C‐LTS)
Number of subjects: 8
Study 27163502 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/LEVO (100/200 μg) as a fixed-dose combination (FDC)
Number of subjects: 30
Study 27163502 — intervention group
Group type: COMPARATOR
Intervention: FF (110 μg)
Number of subjects: 30
Study 27163502 — intervention group
Group type: COMPARATOR
Intervention: LEVO (200 μg)
Number of subjects: 30
Study 27163502 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/LEVO FDC
Number of subjects: 30
Study 27163502 — intervention group
Group type: COMPARATOR
Intervention: FF alone
Number of subjects: 30
Study 25211749 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief interactive intervention (n = 349)
Number of subjects: 702
Study 25211749 — intervention group
Group type: COMPARATOR
Intervention: Attention-equivalent control condition (n = 353)
Number of subjects: 702
Study 22388527 — intervention group
Group type: EXPERIMENTAL
Intervention: Replicating Effective Programs-Facilitation
Number of subjects: 50
Study 20547984 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) 20 mg/m²/d plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 107
Study 20547984 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 107
Study 20547984 — intervention group
Group type: EXPERIMENTAL
Intervention: All-trans retinoic acid (ATRA) plus chemotherapy (cisplatin and paclitaxel)
Number of subjects: 107
Study 18665031 — intervention group
Group type: EXPERIMENTAL
Intervention: Eutectic mixture of local anesthetics (EMLA)
Number of subjects: 41
Study 18665031 — intervention group
Group type: COMPARATOR
Intervention: Ametop
Number of subjects: 41
Study 16061839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic 2.5% testosterone gel applied to scrotal skin (1 g, n = 54)
Number of subjects: 162
Study 16061839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic 2.5% testosterone gel applied to non-scrotal skin (5 g, n = 56)
Number of subjects: 162
Study 16061839 — intervention group
Group type: COMPARATOR
Intervention: Androderm patches (2 patches/day, n = 52)
Number of subjects: 162
Study 16061839 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroalcoholic 2.5% testosterone gel (scrotal and non-scrotal)
Number of subjects: 162
Study 16061839 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (scrotal gel, non-scrotal gel, patch)
Number of subjects: 162
Study 11810598 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleoside analogues (NAs)
Number of subjects: 120
Study 11810598 — intervention group
Group type: COMPARATOR
Intervention: NAs only
Number of subjects: 120
Study 11810598 — intervention group
Group type: EXPERIMENTAL
Intervention: Stavudine and didanosine
Number of subjects: 120
Study 11810598 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 120
Study 11810598 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV RNA level at month 30
Number of subjects: 120
Study 11810598 — intervention group
Group type: EXPERIMENTAL
Intervention: Any antiretroviral exposure
Number of subjects: 120
Study 9020241 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based dietary management system
Number of subjects: 814
Study 9020241 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported reductions in intake of dietary saturated fat and cholesterol
Number of subjects: 814
Study 7807189 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0
Study 7807189 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 0
Study 7807189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing trials
Number of subjects: 0
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg daily
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, 325 mg three times daily
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole (325 mg and 75 mg, respectively, three times daily)
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone (267 mg three times daily)
Number of subjects: 555
Study 3286040 — intervention group
Group type: COMPARATOR
Intervention: Placebo (three times daily)
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin daily
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin three times daily
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin plus dipyridamole
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfinpyrazone
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: All aspirin-containing regimens
Number of subjects: 555
Study 3286040 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall operative mortality
Number of subjects: 555
Study 30778004 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lifestyle modification (ILSM)
Number of subjects: 103
Study 30778004 — intervention group
Group type: EXPERIMENTAL
Intervention: ILSM and metformin (ILSM+Met)
Number of subjects: 103
Study 30778004 — intervention group
Group type: COMPARATOR
Intervention: Standard care (STD)
Number of subjects: 103
Study 27734980 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids + Kabat physical rehabilitation
Number of subjects: 94
Study 27734980 — intervention group
Group type: COMPARATOR
Intervention: Steroids alone
Number of subjects: 94
Study 24518152 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose grape seed extract (200 mg/d)
Number of subjects: 96
Study 24518152 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose grape seed extract (100 mg/d)
Number of subjects: 96
Study 24518152 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 23329572 — intervention group
Group type: EXPERIMENTAL
Intervention: Transplantation of autologous mesenchymal stem cells (MSCs) from G-CSF-mobilised peripheral blood
Number of subjects: 21
Study 23329572 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 21
Study 20826993 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band UV-B (TL-01) phototherapy, twice-weekly for 3 months
Number of subjects: 60
Study 20826993 — intervention group
Group type: COMPARATOR
Intervention: Oral 8-Methoxsalen PUVA, twice-weekly for 3 months
Number of subjects: 60
Study 18777217 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based HIV prevention trial
Number of subjects: 2623
Study 16698007 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 200 mg/day
Number of subjects: 28
Study 16698007 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C 1 g/day
Number of subjects: 28
Study 16698007 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E 400 mg/day
Number of subjects: 28
Study 16698007 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 28
Study 14761123 — intervention group
Group type: EXPERIMENTAL
Intervention: Smokers
Number of subjects: 22
Study 14761123 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 22
Study 11168196 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous bone grafts (group 1)
Number of subjects: 18
Study 11168196 — intervention group
Group type: COMPARATOR
Intervention: Revascularized free flaps (group 2)
Number of subjects: 18
Study 8739759 — intervention group
Group type: EXPERIMENTAL
Intervention: Palm sweating (PS) measured using hygrometry during short-term memory tasks.
Number of subjects: 6
Study 8225684 — intervention group
Group type: EXPERIMENTAL
Intervention: Voltaren (V) 100 mg tablet
Number of subjects: 15
Study 8225684 — intervention group
Group type: COMPARATOR
Intervention: Diclogesic (D) 100 mg tablet
Number of subjects: 15
Study 3100463 — intervention group
Group type: EXPERIMENTAL
Intervention: Mequitazine 5 mg
Number of subjects: 9
Study 3100463 — intervention group
Group type: EXPERIMENTAL
Intervention: Astemizole 10 mg
Number of subjects: 9
Study 3100463 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 29384762 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gait training coupled with virtual reality
Number of subjects: 45
Study 29384762 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional rehabilitative treatment)
Number of subjects: 45
Study 27356528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium and bicarbonate mineral water (BW, sodium 1 g/L; bicarbonate 2 g/L)
Number of subjects: 21
Study 27356528 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium and bicarbonate mineral water (BW) with meal
Number of subjects: 21
Study 27356528 — intervention group
Group type: COMPARATOR
Intervention: Low-mineral content control water (CW)
Number of subjects: 21
Study 24670999 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented Reality Ophthalmoscopy (ARO)
Number of subjects: 37
Study 24670999 — intervention group
Group type: COMPARATOR
Intervention: Conventional Ophthalmoscopy
Number of subjects: 37
Study 23140347 — intervention group
Group type: EXPERIMENTAL
Intervention: ICD therapy (112 patients, 22.5% of total)
Number of subjects: 497
Study 23140347 — intervention group
Group type: COMPARATOR
Intervention: Non-ICD therapy (385 patients)
Number of subjects: 497
Study 23140347 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate
Number of subjects: 497
Study 23140347 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of sudden cardiac death
Number of subjects: 497
Study 20358312 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Anganwadi centers
Number of subjects: 80
Study 20358312 — intervention group
Group type: COMPARATOR
Intervention: Control Anganwadi centers
Number of subjects: 80
Study 18660395 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgeon-performed ultrasound
Number of subjects: 800
Study 18660395 — intervention group
Group type: COMPARATOR
Intervention: Standard examination without ultrasound
Number of subjects: 800
Study 15735389 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral electrovaporization of the prostate (TUVP)
Number of subjects: 77
Study 15735389 — intervention group
Group type: COMPARATOR
Intervention: Standard transurethral prostatectomy (TURP)
Number of subjects: 77
Study 15735389 — intervention group
Group type: EXPERIMENTAL
Intervention: TUVP
Number of subjects: 77
Study 15735389 — intervention group
Group type: COMPARATOR
Intervention: TURP
Number of subjects: 77
Study 15735389 — intervention group
Group type: EXPERIMENTAL
Intervention: TUVP and TURP
Number of subjects: 77
Study 12358251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod 2 or 6 mg b.i.d. (n = 1679)
Number of subjects: 2516
Study 12358251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 837)
Number of subjects: 2516
Study 12358251 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegaserod iv. single doses (0.8 mg to 20 mg)
Number of subjects: 2516
Study 12358251 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in healthy subjects)
Number of subjects: 2516
Study 10356912 — intervention group
Group type: EXPERIMENTAL
Intervention: Admission and discharge values of rosette formation, adhesive and phagocytic ability of neutrophils
Number of subjects: 48
Study 10356912 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-5 weeks of hospital stay
Number of subjects: 48
Study 7490317 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple Myeloma
Number of subjects: 35
Study 7490317 — intervention group
Group type: EXPERIMENTAL
Intervention: MGUS
Number of subjects: 35
Study 7490317 — intervention group
Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 35
Study 1664903 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH) subfraction, initial dose of 17 to 95 U/kg and continuous dose of 7 to 20 U/kg/hr
Number of subjects: 10
Study 1664903 — intervention group
Group type: COMPARATOR
Intervention: Standard heparin
Number of subjects: 10
Study 7247733 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate 300mg daily for 1 year
Number of subjects: 0
Study 31235156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT)
Number of subjects: 55
Study 31235156 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 55
Study 27889545 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 215
Study 27889545 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 215
Study 26359512 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg (high-dose statin therapy)
Number of subjects: 60
Study 26359512 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin 20 mg (low-dose statin therapy)
Number of subjects: 60
Study 23401294 — intervention group
Group type: EXPERIMENTAL
Intervention: Posture-training support
Number of subjects: 18
Study 23401294 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinomed orthosis
Number of subjects: 18
Study 23401294 — intervention group
Group type: COMPARATOR
Intervention: Spinomed orthosis and posture-training support
Number of subjects: 18
Study 20951997 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 20
Study 20951997 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 20
Study 18408861 — intervention group
Group type: EXPERIMENTAL
Intervention: Phonological remediation program (Gonzalez & Rosquete, 2002)
Number of subjects: 24
Study 16549997 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib (250 mg/day)
Number of subjects: 141
Study 16549997 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel (75 mg/m2 every 3 weeks)
Number of subjects: 141
Study 14739683 — intervention group
Group type: EXPERIMENTAL
Intervention: Agalsidase alfa enzyme replacement therapy
Number of subjects: 15
Study 14739683 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 10801172 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (20 Gy in ten fractions)
Number of subjects: 30
Study 10801172 — intervention group
Group type: COMPARATOR
Intervention: Sham-irradiation (ten fractions of 0 Gy)
Number of subjects: 30
Study 10801172 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 30
Study 10801172 — intervention group
Group type: COMPARATOR
Intervention: Sham-irradiation
Number of subjects: 30
Study 8839837 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose sIL-1RI
Number of subjects: 18
Study 8839837 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose sIL-1RI
Number of subjects: 18
Study 8839837 — intervention group
Group type: EXPERIMENTAL
Intervention: sIL-1RI (both doses)
Number of subjects: 18
Study 8839837 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1626735 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 units intravenously over five minutes)
Number of subjects: 110
Study 1626735 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase (750,000 units intravenously over thirty to sixty minutes)
Number of subjects: 110
Study 1626735 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase
Number of subjects: 110
Study 1626735 — intervention group
Group type: COMPARATOR
Intervention: Streptokinase
Number of subjects: 110
Study 1626735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 110
Study 6385681 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem, 360 mg/day
Number of subjects: 17
Study 6385681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31786030 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine 0.5 mg/kg
Number of subjects: 63
Study 31786030 — intervention group
Group type: COMPARATOR
Intervention: Esketamine 0.25 mg/kg
Number of subjects: 63
Study 29551030 — intervention group
Group type: EXPERIMENTAL
Intervention: Eltrombopag (25 mg/d)
Number of subjects: 35
Study 29551030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 27101291 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise followed by resistance exercise (AE + RE)
Number of subjects: 10
Study 27101291 — intervention group
Group type: COMPARATOR
Intervention: Resistance exercise only (RE)
Number of subjects: 10
Study 26200539 — intervention group
Group type: EXPERIMENTAL
Intervention: Transperitoneal (TP) approach
Number of subjects: 62
Study 26200539 — intervention group
Group type: COMPARATOR
Intervention: Extraperitoneal (EP) approach
Number of subjects: 62
Study 23857041 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic titration guided by the BIS (dual-loop group)
Number of subjects: 67
Study 23857041 — intervention group
Group type: COMPARATOR
Intervention: Manual target-controlled infusion of propofol and remifentanil (manual TCI group)
Number of subjects: 67
Study 20956635 — intervention group
Group type: COMPARATOR
Intervention: Fixed starting dose
Number of subjects: 210
Study 20956635 — intervention group
Group type: COMPARATOR
Intervention: 70% of individual MED
Number of subjects: 210
Study 20956635 — intervention group
Group type: COMPARATOR
Intervention: 50% of individual MED
Number of subjects: 210
Study 18720268 — intervention group
Group type: EXPERIMENTAL
Intervention: Heroin dependence
Number of subjects: 16
Study 17026488 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/MET fixed-dose combination therapy (AVANDAMET) 4 mg/1000 mg up-titrated to 8 mg/2000 mg
Number of subjects: 190
Study 17026488 — intervention group
Group type: EXPERIMENTAL
Intervention: RSG/MET fixed-dose combination therapy (AVANDAMET)
Number of subjects: 190
Study 15058690 — intervention group
Group type: EXPERIMENTAL
Intervention: Category learning task
Number of subjects: 0
Study 15058690 — intervention group
Group type: COMPARATOR
Intervention: 5-4 categories
Number of subjects: 0
Study 10722500 — intervention group
Group type: EXPERIMENTAL
Intervention: Amprenavir, 1,200 mg twice daily over 4 days (seven doses)
Number of subjects: 14
Study 10722500 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin, 500 mg twice daily over 4 days (seven doses)
Number of subjects: 14
Study 10722500 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of amprenavir and clarithromycin over 4 days (seven doses of each drug)
Number of subjects: 14
Study 10722500 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 14
Study 8737758 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 18
Study 8737758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 1444526 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg IVIG at two week intervals
Number of subjects: 36
Study 1444526 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 3932106 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexchlorpheniramine maleate 6 mg b.i.d.
Number of subjects: 174